RxAlly names Tom O'Grady to leadership team

Tuesday, July 17, 2012 12:12 PM

RxAlly, a first-of-its-kind alliance of more than 22,000 pharmacies nationwide, has named Tom O'Grady to its leadership team.  As general counsel and executive vice president of corporate development, O’Grady brings more than 30 years of corporate and transactional law experience. He will be structuring business relationships between RxAlly and the companies and businesses it will be working with as it continues to align pharmacies and pharmacists, the patients they serve and the payer community.

O'Grady joins RxAlly from McGuireWoods, where he focused on transactional law for health care and other technology-enabled companies for 26 years. Previously, he practiced in South Africa, where he became a partner in Bowman Gilfillan, one of South Africa's largest law firms. He spent a year at Wall Street law firm Shearman & Sterling.

RxAlly is a performance network of more than 22,000 member pharmacies nationwide, united to help patients achieve better health while reducing costs. RxAlly aims to improve health through personalized pharmacist care, clinical research and evidence-based clinical practices, and an interoperable technology platform.

 

Share:          
CWWeekly

April 13

Quintiles-Quest Diagnostics joint venture latest in CRO-central lab deals, more could be on horizon

Biotech companies raise record amount of capital in Q1

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

April

PSI, INC Research, Chiltern best with sites
Strategic outsourcing prioritizing, improving site relationships

Regulatory compliance an increasing burden on sites
Increased staff time, materials, storage eroding site operating profit

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

March

Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs